News Search Results
Nov 04, 2025, 16:01 ET Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update
ocadusertib. In early October, Rigel received notification from Lilly that it will terminate the central nervous system (CNS) disease program related to the collaboration between the two companies, which will become effective 60 days following notification.
More news about: Rigel Pharmaceuticals, Inc.
Nov 04, 2025, 07:00 ET NewcelX CEO Issues Letter to Shareholders
neurodegenerative diseases. The DOXA program gives NewcelX a pipeline engine with the potential to generate multiple assets across Central Nervous System (CNS) and metabolic disorders. The scientific horizon here is wide, and the commercial opportunities reach large, underserved populations.
More news about: NewcelX Ltd.
Nov 03, 2025, 19:00 ET Kaigene Enters into Exclusive Licensing Agreement with Celltrion for Novel Antibody Therapeutics in Autoimmune Diseases
barrier. Through this platform, the company is developing multiple therapeutic candidates aimed at addressing the significant unmet clinical needs in CNS autoimmune diseases, an area that remains largely unexplored. Founded in 2022, Kaigene is currently in the Pre-A bridging investment stage and has raised
More news about: Kaigene
Nov 03, 2025, 17:31 ET Chronic Progressive Multiple Sclerosis Market to Witness Accelerated Expansion During the Forecast Period (2025-2034) Due to Strong Pipeline and Advanced Therapeutic Strategies | DelveInsight
Tolebrutinib is an investigational oral BTK inhibitor specifically developed to cross the blood–brain barrier and remain active within the central nervous system (CNS). Its goal is to target smoldering neuroinflammation, a key driver of disability progression in multiple sclerosis. In contrast to conventional multiple
More news about: DelveInsight Business Research, LLP
Nov 03, 2025, 14:23 ET Vascarta Inc: Transdermal Curcumin (VAS-101 Drug Candidate) Interrupts the Neuroinflammatory Pathophysiological Cascade Associated with Acute Sickle Cell Crisis
mitochondrial membrane potential. The investigators conclude that IL-17 orchestrates acute pain by promoting the IL-17-TNF-α/IL-6–p38 cascade in the CNS and periphery, leading to oxidative stress and mitochondrial dysfunction in sensory neurons. VAS-101 interrupts this SCD pathophysiological cascade,
More news about: Vascarta Inc
Nov 03, 2025, 08:08 ET Eisai Demonstrates Commitment to Advanced Endometrial Cancer Care at IGCS 2025
3-5 hemorrhage occurred in 2% of LENVIMA-treated patients, including 1 fatal intracranial hemorrhage among 16 patients who received LENVIMA and had CNS metastases at baseline. In RCC, grade 3-5 hemorrhage occurred in 8% of LENVIMA + everolimus–treated patients, including 1 fatal cerebral hemorrhage.
More news about: Eisai Inc.
Nov 03, 2025, 08:00 ET Servier Announces Positive Findings from Longer-Term Analysis of the Phase 3 INDIGO Trial Showing Continued Durable Treatment Effect of VORANIGO® (vorasidenib) Published in The Lancet Oncology
Astrocytoma, IDH-mutant (CNS WHO grades 2-4) Oligodendroglioma, IDH-mutant and1p19q-codeleted (CNS WHO grades 2-3) Glioblastoma, IDH-wildtype (CNS WHO grade 4)
More news about: Servier Pharmaceuticals
Nov 03, 2025, 08:00 ET Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine
and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE. Risk of Serious Injection Site Reactions: Likelihood of may
More news about: Indivior PLC
Oct 31, 2025, 11:50 ET The Galien Foundation Honors Michael J. Fox and 2025 Prix Galien Award Recipients
Jamey EDWARDSFormer CEO, Emergent Medical Associates Amir KALALIM.D., Chairman & Chief Curator CNS Summit/Co-Chair Decentralized Trial Research Alliance Michelle LONGMIREM.D., Co-Founder & CEO, Medable
More news about: The Galien Foundation
Oct 31, 2025, 09:00 ET Zhimeng Biopharma's investigational drug CB03-154 for amyotrophic lateral sclerosis has achieved the first patient first dose milestone in the phase 2/3 pivotal clinical trial.
dedicated to develop small-molecule drug discovery with focused on the functional cure of chronic hepatitis B (CHB), as well as novel therapies for CNS disorders, including epilepsy, neuropathic pain (e.g. cancer-related pain), amyotrophic lateral sclerosis (ALS), major depressive disorder (MDD), and
More news about: Shanghai Zhimeng Biopharma Inc.
Oct 31, 2025, 08:00 ET Servier's VORANIGO® (vorasidenib) Receives Prestigious 2025 Prix Galien USA Award
1 Gliomas are tumors that arise from glial or precursor cells within the central nervous system (CNS). The 2021 World Health Organization (WHO) classification recognizes four general groups of gliomas, one of which is adult-type diffuse gliomas. These
More news about: Servier Pharmaceuticals
Oct 30, 2025, 17:31 ET Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight
The atypical teratoid/rhabdoid tumor market growth is driven by rising molecular diagnosis and increased awareness of this aggressive pediatric CNS cancer, which is expanding the pool of identified patients. Additionally, the launch of emerging therapies such as PD-1 inhibitor (Nivolumab), Aurora
More news about: DelveInsight Business Research, LLP
Oct 30, 2025, 16:22 ET Cohen & Steers, Inc. Declares Quarterly Dividend
NEW YORK, Oct. 30, 2025 /PRNewswire/ -- The Board of Directors of Cohen & Steers, Inc. (NYSE: CNS) declared a cash dividend for the fourth quarter of 2025 in the amount of $0.62 per share of common stock payable on November 20, 2025, to stockholders
More news about: Cohen & Steers, Inc.
Oct 30, 2025, 09:00 ET Signant Health Appoints Internationally Recognized Cognitive Assessment Expert John Harrison to Further Advance Innovation in CNS Clinical Trials
Harrison. "I'm excited to join Signant at this pivotal time and work alongside the team to advance how we measure and interpret cognitive outcomes in CNS trials. Signant's commitment to scientific rigor and its deep therapeutic expertise make it the ideal partner for sponsors developing the next generation
More news about: Signant Health
Oct 30, 2025, 07:00 ET NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
central nervous system and neurodegenerative disorders, and Aexon Labs, a biotechnology company advancing next-generation central nervous system ("CNS") therapeutics, today announced the expansion of their DOXA platform with the AEX-6xx series, a new generation of small molecules targeting arousal stability,
More news about: NLS Pharmaceutics Ltd.
Oct 30, 2025, 06:30 ET Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results
intracranial regression at their clinically relevant doses. Additionally, NVL-330 induced intracranial tumor regression in mice that had progressed in the CNS on zongertinib. These data add to the preclinical characterization of NVL-330 as a brain penetrant TKI that is broadly active against HER2 oncogenic
More news about: Nuvalent, Inc.
Oct 29, 2025, 09:55 ET Connected Nation highlights Cybersecurity Awareness Month with intergenerational internet safety event in Dallas
adults and older adults gain the skills to use technology safely, confidently and meaningfully." The Dallas event underscored CN's commitment to advancing digital safety, inclusion, and empowerment nationwide. Through Teens Teach Tech, powered by AT&T, more than 150 youth teams
More news about: Connected Nation
Oct 29, 2025, 08:30 ET Miami Biotech Collective Introduces Board of Advisors and Women's Leadership Council to Shape South Florida's Biotech Future
CNS2, is an entrepreneur and life sciences innovator, recognized among the Top 10 Inspirational Women in Nordic Life Science (2023) and Endpoints 20 Under
More news about: Miami Biotech Collective
Oct 28, 2025, 17:07 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Oct 28, 2025, 17:00 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Oct 28, 2025, 17:00 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Oct 28, 2025, 16:53 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Oct 28, 2025, 16:51 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Oct 28, 2025, 11:56 ET New SK Life Science, Inc. Survey Reveals Communication Gaps Between Patients and Providers That Can Impact Epilepsy Care Outcomes
SK Life Science, Inc., a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., reveal striking communication gaps between patients and providers that can stand in the
More news about: SK Life Science, Inc.
Oct 28, 2025, 09:15 ET AI Set to Transform Pediatric Neuro-Oncology: A New Era in Treatment and Assessment
equitable access so that AI tools are safe, effective, and trustworthy at the point of care. Pediatric central nervous system (CNS) tumors are the most common solid tumors in children and adolescents, with approximately 48,000 new cases annually worldwide. Prognosis varies due to
More news about: Children's Hospital of Philadelphia